A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients With Advanced Solid Tumors and Varying Degrees of Renal Impairment
Phase of Trial: Phase I
Latest Information Update: 21 Jun 2017
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Taiho Pharmaceutical
- 12 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Nov 2017.
- 12 Jun 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Nov 2017.
- 09 Jun 2015 In the treatment table, 4th arm for normal hepatic function has been added as reported by ClinicalTrials.gov